U.S. Markets closed

Sunshine Biopharma, Inc. (SBFM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0285-0.0005 (-1.72%)
At close: 3:59PM EST

Sunshine Biopharma, Inc.

6500 Trans-Canada Highway
4th Floor
Pointe-Claire, QC H9R 0A5
Canada
514 426 6161
http://www.sunshinebiopharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Dr. Steve N. SlilatyChairman, CEO & Pres28kN/A1952
Mr. Camille SebaalyCFO, Sec. & Director25kN/A1959
Dr. Abderrazzak MerzoukiCOO & Director19.92kN/A1964
Mr. Robert G. FerreiraPres of Sunshine Bio Investments IncN/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on development of anticancer drug. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells. It also provides generic prescription drugs for the treatment of breast cancer, prostate cancer, and benign prostatic hyperplasia; chemical analysis of pharmaceutical and other industrial samples; and Essential 9, a dietary supplement. Sunshine Biopharma, Inc. has an agreement with the University of Georgia to advance the development of Sunshine Biopharma's announced anti-Coronavirus lead compound, SBFM-PL4. The company is based in Pointe-Claire, Canada.

Corporate Governance

Sunshine Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.